Prz Menopauzalny. 2014 Dec;13(6):348-51. doi: 10.5114/pm.2014.47988. Epub  2014 Dec 30.
 
- 1Department
 of Laboratory Diagnostics, Medical University of Lublin, Poland ; 
Department of Endocrinology, Medical University of Lublin, Poland.
- 2Department of Endocrinology, Medical University of Lublin, Poland.
- 33 Chair and Department of Gynecology, Medical University of Lublin, Poland.
- 4Department of Laboratory Diagnostics, Medical University of Lublin, Poland.
 
 
Abstract
Polycystic
 ovary syndrome (PCOS), a hyperandrogenic disorder, is the commonest 
endocrinopathy in premenopausal women. This syndrome is associated with fertility
 problems, clinical manifestations of hyperandrogenism and metabolic 
disturbances, particularly insulin resistance and obesity. There is a 
great body of evidence that patients with PCOS present multiple 
cardiovascular risk factors and cluster components of metabolic syndrome
 from early ages. The presence of comorbidities such as abdominal 
obesity, insulin resistance, type 2 diabetes, hypertension places these 
females at an increased risk of future cardiovascular events. However, 
the extent to which PCOS components are present in perimenopausal women 
and the degree to which PCOS increases various risk factors in addition 
to the known risk of the perimenopausal period have not been fully 
determined. The perimenopausal period per se is associated with weight 
gain and an increased cardiovascular risk, which may be additionally 
aggravated by the presence of metabolic disturbances connected with 
PCOS. The phenotype of PCOS may improve with aging and it is still 
uncertain whether the presence of PCOS significantly increases the 
cardiovascular risk later in women's life. Most recent data suggest that
 the prevalence of cardiovascular diseases and the related long-term 
consequences in females with PCOS seem to be lower than expected. This 
manuscript reviews long-term consequences of PCOS and considers their 
clinical implications in perimenopause.  
 
KEYWORDS: 
PCOS; cardiovascular risk; insulin resistance; menopause; perimenopause